focus -WSS

focus

author：hotspot 2025-10-01 17:20:14 - browse：78366

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： How to increase colonoscopy rates? Looks like an AI can help

hotspot

WSS

Why we need mandatory labeling of GMO products

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Pharma’s losing bet in New Jersey

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

BMI, flaws aside, is found to be useful estimate of body fat in youth

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

entertainment

focus

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Decentralized clinical trials need collaboration to achieve wider use

Apple is now the first public company to be valued at $3 trillion

New research sheds light on how often breast cancer is overdiagnosed

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The Bio Revolution is changing business and society

Hollywood unions extend contract negotiations for actors

Pharma’s losing bet in New Jersey

Malaria cases in Florida and Texas: Here’s what you need to know

Ionis drug prevents swelling attacks due to hereditary angioedema

focus

Letters to First Opinion on caregivers, digital health, and more

Pharma’s losing bet in New Jersey

With trial win, GSK could get blood cancer drug back on market

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Achieving telehealth equity for people with hearing loss

The Pandemic Treaty must support building strong health systems

hotspot

hotspot

hotspot

Wikipedia